Abstract

BackgroundThe Pap test has been used for cervical cancer screening for more than four decades. A human papillomavirus (HPV) vaccine has been approved for use in Canada and is commercially available now. These two preventive interventions should be considered simultaneously. General population support is an important factor for the successful combination of these interventions. The study had two objectives: 1) To assess practices, beliefs, and attitudes regarding Pap test screening and HPV immunization; 2) To identify socio-demographic factors for Pap screening and vaccine acceptability.MethodsIn 2006, 500 adults were invited to participate in a telephone survey in the region of Quebec City (urban and rural population, 600 000), Canada. Some neutral and standardized information on Pap test and HPV was provided before soliciting opinions.Results471 adults (18–69 year-olds) answered the questionnaire, the mean age was 45 years, 67% were female, and 65% had college or university degree. Eighty-six percent of women had undergone at least one Pap-test in their life, 55% in the last year, and 15% from 1 to 3 years ago. Among screened women, the test had been performed in the last three years in 100% of 18–30 year-olds, but only in 67% of 60–69 year-olds (P < 0.0001). Only 15% of respondents had heard of HPV. Eighty-seven percent agreed that HPV vaccines could prevent cervical cancer, 73% that the vaccine has to be administered before the onset of sexual activity, 89% would recommend vaccination to their daughters and nieces. Among respondents < 25 years, 91% would agree to receive the vaccine if it is publicly funded, but only 72% would agree to pay $100/dose.ConclusionThere is an important heterogeneity in cervical cancer screening frequency and coverage. Despite low awareness of HPV infection, the majority of respondents would recommend or are ready to receive the HPV vaccine, but the cost could prevent its acceptability.

Highlights

  • The Pap test has been used for cervical cancer screening for more than four decades

  • The Human papillomavirus (HPV) vaccines, if widely used, have the potential to prevent thousands of cases of cervical cancer worldwide, as well as to substantially reduce costs and emotional stress associated with abnormal screening test (Pap) results[9,10]

  • The surveys show that awareness about HPV is very low and that many women are shocked to discover that cervical cancer is caused by a sexually transmitted infection (STI)

Read more

Summary

Introduction

The Pap test has been used for cervical cancer screening for more than four decades. A human papillomavirus (HPV) vaccine has been approved for use in Canada and is commercially available now. A human papillomavirus (HPV) vaccine has been approved for use in Canada and is commercially available These two preventive interventions should be considered simultaneously. Genital Human papillomavirus (HPV) infection is the most common sexually transmitted infection (STI). The HPV vaccines, if widely used, have the potential to prevent thousands of cases of cervical cancer worldwide, as well as to substantially reduce costs and emotional stress associated with abnormal screening test (Pap) results[9,10].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call